OCUL
OCULAR THERAPEUTIX, INC
NASDAQ · Healthcare · Biotechnology · US
$7.14
+4.69%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$7.09
From 52W high−55.68%
Volume3.36M
Market cap$1.57B
P/E (TTM)—
P/S (TTM)30.1x
Div yield—
Key dataNov 4, 2026
Open
$7.09
From 52W high
−55.68%
Volume
3.36M
Market cap
$1.57B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
P/E (TTM)
—
RSI (14)
45.6
MomentumView details →
1D Return
+4.69%
YTD Return
−41.60%
SummaryUpdated Jun 1, 2026
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company founded in 2006 and headquartered in Bedford, Massachusetts. The company specializes in developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel-based formulation technology. Since going public in 2014, Ocular Therapeutix has evolved from a clinical-stage company into a commercial organization with marketed products and a robust pipeline of sustained-release drug delivery systems for various ocular conditions.
Similar companies
Latest newsMore news →
Sanjay Nayak resigned as Chief Strategy Officer of OCULAR THERAPEUTIX, INC19d agoOcular Therapeutix completed a positive Pre-NDA meeting with the U.S. FDA for its investigational wet AMD candidate AXPAXLI, confirming plans for a 4Q 2026 NDA submission.51d agoOcular Therapeutix announced that the FDA is aligned on its plan to submit a new drug application for Axpaxli injection for wet age-related macular degeneration.140d ago